Compare TGLS & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGLS | NUVB |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | 298 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2011 | N/A |
| Metric | TGLS | NUVB |
|---|---|---|
| Price | $39.45 | $4.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $63.33 | $11.38 |
| AVG Volume (30 Days) | 309.6K | ★ 4.3M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $370,984,000.00 | N/A |
| Revenue This Year | $13.56 | $203.82 |
| Revenue Next Year | $9.04 | $58.18 |
| P/E Ratio | $54.41 | ★ N/A |
| Revenue Growth | ★ 17.98 | N/A |
| 52 Week Low | $37.52 | $1.57 |
| 52 Week High | $90.34 | $9.75 |
| Indicator | TGLS | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 38.01 |
| Support Level | N/A | $4.07 |
| Resistance Level | $46.89 | $5.23 |
| Average True Range (ATR) | 2.05 | 0.30 |
| MACD | -0.28 | -0.04 |
| Stochastic Oscillator | 20.29 | 15.24 |
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.